XBI: An Equal Weight ETF On Biotech That Amplifies Its Speculative Component

2025-11-16 07:28:11 ET

Those who follow the biotech segment know State Street® SPDR® S&P® Biotech ETF ( XBI ), probably the standard proxy used by long/short biotech funds. What may have gone unnoticed, given the widespread pessimism behind the healthcare sector, is the fact that YTD, XBI has recorded almost a 30% gain, away from the market spotlight. And the question arises spontaneously: are we talking about a potential bullish cycle or a false alarm? Well, we all know that in this sector, we think in cyclical terms, and as I see it, a certain market timing is essential. But wanting to give you my opinion, I see some positive clues....

Read the full article on Seeking Alpha

For further details see: